A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

@article{Serretta2012ART,
  title={A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.},
  author={Vincenzo Serretta and Vincenzo Altieri and Giuseppe Morgia and Federico Nicolosi and Gaetano De Grande and Rosaria Mazza and Darwin Melloni and Rosalinda Allegro and Francesco Ferra{\`u} and Vittorio Gebbia},
  journal={Clinical genitourinary cancer},
  year={2012},
  volume={10 3},
  pages={174-9}
}
BACKGROUND Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS One hundred seventy-six patients with prostate cancer (PC… CONTINUE READING